Overview

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Status:
Recruiting

Trial end date:
2028-09-01

Target enrollment:

Participant gender:

Summary

To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Acetaminophen
Axicabtagene ciloleucel
Cyclophosphamide
Diphenhydramine
Fludarabine
Fludarabine phosphate
Prednisone
Promethazine